Torcetrapib lowers blood glucose rates in type 2 diabetes

07/18/2011 | HealthDay News

Taking the cholesterol drug torcetrapib was more effective than a placebo in lowering blood glucose levels in patients with type 2 diabetes, an Australian study in Circulation found. Torcetrapib-treated patients had an average hemoglobin A1c of 7.06% at the end of the study, compared with 7.29% in those who took a placebo, experts said. The drug, however, increases the risk of cardiovascular problems and death. "This won't change practice for now," endocrinologist Spyros Mezitis said. "We need more studies to understand the pathophysiology, and we need solid cardiovascular evidence for the other agents in this class."

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA